Leslie R Harrold1,2, Heather J Litman3,4, Sean E Connolly3,4, Sheila Kelly3,4, Winnie Hua3,4, Evo Alemao3,4, Lisa Rosenblatt3,4, Sabrina Rebello3,4, Joel M Kremer3,4. 1. From the University of Massachusetts Medical School, Worcester; Corrona LLC, Southborough, Massachusetts; Bristol-Myers Squibb, Princeton, New Jersey; Albany Medical College and The Center for Rheumatology, Albany, New York. Leslie.Harrold@umassmed.edu. 2. L.R. Harrold, MD, MPH, University of Massachusetts Medical School, and Corrona LLC; H.J. Litman, PhD, Corrona LLC; S.E. Connolly, PhD, Bristol-Myers Squibb; S. Kelly, MD, Bristol-Myers Squibb; W. Hua, MS, Corrona LLC; E. Alemao, MS, RPh, Bristol-Myers Squibb; L. Rosenblatt, MD, MPH, Bristol-Myers Squibb; S. Rebello, MPH, Corrona LLC; J.M. Kremer, MD, Corrona LLC, and Albany Medical College and The Center for Rheumatology. Leslie.Harrold@umassmed.edu. 3. From the University of Massachusetts Medical School, Worcester; Corrona LLC, Southborough, Massachusetts; Bristol-Myers Squibb, Princeton, New Jersey; Albany Medical College and The Center for Rheumatology, Albany, New York. 4. L.R. Harrold, MD, MPH, University of Massachusetts Medical School, and Corrona LLC; H.J. Litman, PhD, Corrona LLC; S.E. Connolly, PhD, Bristol-Myers Squibb; S. Kelly, MD, Bristol-Myers Squibb; W. Hua, MS, Corrona LLC; E. Alemao, MS, RPh, Bristol-Myers Squibb; L. Rosenblatt, MD, MPH, Bristol-Myers Squibb; S. Rebello, MPH, Corrona LLC; J.M. Kremer, MD, Corrona LLC, and Albany Medical College and The Center for Rheumatology.
Abstract
OBJECTIVE: Assess whether baseline anticyclic citrullinated peptide antibodies (anti-CCP) status is associated with treatment response in patients with rheumatoid arthritis (RA) initiating abatacept (ABA) or a tumor necrosis factor-α inhibitor (TNFi). METHODS: Using the Corrona RA registry, patients were identified who initiated ABA or a TNFi (June 2004-January 2015), had a followup visit 6 months (± 3 mos) after initiation, and anti-CCP measured at or prior to initiation. Primary outcome was mean change in Clinical Disease Activity Index (CDAI) from initiation to 6 months. Treatment response was evaluated based on a typical patient profile (female, aged 57 yrs, body mass index of 30 kg/m2, baseline CDAI of 20, 1 prior biologic, and no comorbidities other than RA). Secondary outcomes included remission and low disease activity. RESULTS: There were 566 ABA initiators [anti-CCP+ (≥ 20 units/ml): n = 362; anti-CCP- (< 20 units/ml): n = 204] and 1715 TNFi initiators (anti-CCP+: n = 1113; anti-CCP-: n = 602). Differences between treatment groups included baseline disease duration, CDAI, and prior biologic use. At 6 months, anti-CCP+ ABA initiators were associated with significantly greater CDAI response versus anti-CCP- ABA initiators; no significant difference was observed for TNFi initiators. When considering a typical RA patient profile, CDAI response was greater in anti-CCP+ versus anti-CCP- ABA initiators; anti-CCP+ versus anti-CCP- TNFi initiators were similar. Secondary outcome responses were also greater in anti-CCP+ versus anti-CCP- ABA initiators; TNFi initiators did not differ by anti-CCP status. CONCLUSION: In a US-based clinical practice setting, anti-CCP status was associated with a differential treatment response to ABA, but not TNFi.
OBJECTIVE: Assess whether baseline anticyclic citrullinated peptide antibodies (anti-CCP) status is associated with treatment response in patients with rheumatoid arthritis (RA) initiating abatacept (ABA) or a tumor necrosis factor-α inhibitor (TNFi). METHODS: Using the Corrona RA registry, patients were identified who initiated ABA or a TNFi (June 2004-January 2015), had a followup visit 6 months (± 3 mos) after initiation, and anti-CCP measured at or prior to initiation. Primary outcome was mean change in Clinical Disease Activity Index (CDAI) from initiation to 6 months. Treatment response was evaluated based on a typical patient profile (female, aged 57 yrs, body mass index of 30 kg/m2, baseline CDAI of 20, 1 prior biologic, and no comorbidities other than RA). Secondary outcomes included remission and low disease activity. RESULTS: There were 566 ABA initiators [anti-CCP+ (≥ 20 units/ml): n = 362; anti-CCP- (< 20 units/ml): n = 204] and 1715 TNFi initiators (anti-CCP+: n = 1113; anti-CCP-: n = 602). Differences between treatment groups included baseline disease duration, CDAI, and prior biologic use. At 6 months, anti-CCP+ ABA initiators were associated with significantly greater CDAI response versus anti-CCP- ABA initiators; no significant difference was observed for TNFi initiators. When considering a typical RApatient profile, CDAI response was greater in anti-CCP+ versus anti-CCP- ABA initiators; anti-CCP+ versus anti-CCP- TNFi initiators were similar. Secondary outcome responses were also greater in anti-CCP+ versus anti-CCP- ABA initiators; TNFi initiators did not differ by anti-CCP status. CONCLUSION: In a US-based clinical practice setting, anti-CCP status was associated with a differential treatment response to ABA, but not TNFi.
Authors: Nathalie E Marchand; Jeffrey A Sparks; Sara K Tedeschi; Susan Malspeis; Karen H Costenbader; Elizabeth W Karlson; Bing Lu Journal: J Rheumatol Date: 2020-07-15 Impact factor: 4.666
Authors: Markus Rehberg; Clemens Giegerich; Amy Praestgaard; Hubert van Hoogstraten; Melitza Iglesias-Rodriguez; Jeffrey R Curtis; Jacques-Eric Gottenberg; Andreas Schwarting; Santos Castañeda; Andrea Rubbert-Roth; Ernest H S Choy Journal: Rheumatol Ther Date: 2021-09-14
Authors: Valquiria G Dinis; Vilma T Viana; Elaine P Leon; Clóvis A Silva; Carla G Saad; Julio C Moraes; Eloisa S Bonfa; Ana C Medeiros-Ribeiro Journal: Clin Rheumatol Date: 2020-01-11 Impact factor: 2.980
Authors: Leslie R Harrold; Heather J Litman; Sean E Connolly; Evo Alemao; Sheila Kelly; Sabrina Rebello; Winnie Hua; Joel M Kremer Journal: Rheumatol Ther Date: 2019-03-13